Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 4/2011

01.10.2011 | Reproductive Medicine

Schizophrenia and Stein–Leventhal syndrome: comorbidity features

verfasst von: Naira R. Matevosyan

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

To explore shared pathogenesis between schizophrenia and polycistic ovary syndrome (PCOS).

Methods

Ninety-six studies of schizophrenia and PCOS from a mean sample of 139 women are recruited from PubMed and FASTSTATS for geometrical regression analysis. Parametric and observational properties of both diseases (gene polymorphism, monoamines, gonadal steroids, gonadotropins, thyroid hormones, insulin sensitivity index, hirsute index, oligomenorrhea, anhedonia, asociality, apathy, emotional withdrawal, alogia, poor rapport, stereotypical thinking, hyperkinetic reactions, treatment with valproate) are stochastically distributed in the elliptical area.

Results

Results of both analyses suggest that insulin resistance and elevated testosterone are predictive to comorbidity. These associations are stronger with calculation from elliptical model (r 2 = 0.92) than a traditional regression analysis (r 2 = 0.65).

Conclusions

Insulin resistance and elevated testosterone in women contribute in shared pathogenesis of schizophrenia and PCOS. 3D regression analysis shows greater strength of association with the “criterion” value.
Literatur
1.
Agarwal SK, Judd HL, Magoffin DA (1996) A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 81:3686–3691PubMedCrossRef
2.
Arad M, Weiner I (2010) Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis. Neuropsychopharmacology 35(7):1570–1582PubMedCrossRef
3.
Barnes RB (1998) The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies. J Endocrinol Invest 21(9):576–579
4.
Bassett AS, Hodgkinson K, Chow RWC et al (1998) 22q11 deletion syndrome in adults with schizophrenia. Am J of Med Genet Part B: Neuropsychiatr Genet 81(4):328–337CrossRef
5.
Baumgartner A, Gräf KJ, Kürten I et al (1988) The hypothalamic-pituitary-thyroid axis in psychiatric patients and healthy subjects. Repeated measurements of thyroxine, free thyroxine, triiodothyronine, free triiodothyronine, and reverse triiodothyronine in patients with major depressive disorder, schizophrenia and healthy subjects. Psychiatry Res 24(3):283–305CrossRef
6.
7.
Bodén R, Haenni A, Lindström L, Sundström J (2009) Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res 115(203):141–145PubMedCrossRef
8.
Bowden CL, Singh V (2008) Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand 111(s426):13–20CrossRef
9.
Brody EB, Man EB (1950) Thyroid function measured by serum precipitable iodine determinations in schizophrenic patients. The Am J of Psychiatr 107:357–359
10.
Bruce-Jones W, Zolese G, White P (1993) Polycystic ovary syndrome and psychiatric morbidity. J Psychosom Obstet Gynecol 14(2):111–116CrossRef
11.
Canuso CM, Goldstein JM, Wojcik J et al (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatr Res 111(1):11–20CrossRef
12.
Campbell M, Fish B, David R et al (2005) Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Dev Disord 2(4):343–358CrossRef
13.
Carney CP, Jones L, Woolson RF (2007) Medical comorbidity in women and men with schizophrenia. J Gen Intern Med 21(11):1133–1137CrossRef
14.
Chua WL- LC, de Santiago AI, Kulkarni J, et al. Estrogens for schizophrenia. Cochrane Database of Systematic Reviews, 2010; Issue 1
15.
Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane Database Systematic Reviews, 2005; (4):CD004719
16.
Chun-Sen H, Chien-Hua W, Wan-Chun C et al (2010) Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 27(5):300–306PubMedCrossRef
17.
Ciotta L, De Leo V, Galvani F et al (1999) Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. Hum Reprod 14(12):2951–2958PubMedCrossRef
18.
Cohen RZ, Seeman MV, Gotowiec A et al (1999) Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatr 156:1059–1065PubMed
19.
Cooper NJ, Jones DR, Sutton AJ (2005) The use of systematic reviews when designing studies. Clin Trials 2:260–264PubMedCrossRef
20.
21.
Correll C, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Child Adolesc Psychiatr 45(7):771–791CrossRef
22.
Dasgupta A, Singh OP, Rout JK et al (2010) Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatr 34(7):1202–1207CrossRef
23.
DeLisi LE, Smith AB, Razi K et al (2000) Investigation of a candidate gene for schizophrenia on Xq13 previously associated with mental retardation and hypothyroidism. Am J Med Genet 96(3):398–403PubMedCrossRef
24.
Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18(6):774–800PubMedCrossRef
25.
Eaton WW, Byrne M, Ewald H et al (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish National Registers. Am J Psychiatr 163:521–528PubMedCrossRef
26.
Eldar-Geval T, Shoham M, Rösler A et al (2007) Subclinical hypothyroidism in infertile women: the importance of continuous monitoring and the role of the thyrotropin-releasing hormone stimulation test. Gynecol Endocrinol 23(6):332–337CrossRef
27.
Elsenbruch S, Hahn S, Kowalsky D et al (2008) Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:5801–5807CrossRef
28.
Ernst CL, Goldberg JF (2002) The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatr 63(Suppl4):42–55
29.
Farrell K, Antoni MH (2010) Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: bio-behavioral mechanisms and interventions. Fertil Steril 94(5):1565–1574PubMedCrossRef
30.
Feldman D, Goldberg JF (2002) A preliminary study of the relationship between Clozapine-induced weight gain and menstrual irregularities in schizophrenic, schizoaffective, and bipolar women. Ann Clin Psychiatr Clin Psychol-Adult 14(1):17–21
31.
Fisun A (2010) Female-specific health problems in mental patients. Curr Opin Psychiatr 23(4):378–382CrossRef
32.
Fitko R, Jan Kucharski J, Szlezyngier B (1995) The importance of thyroid hormone in experimental ovarian cyst formation in gilts. Animal Reprod Sci 39(2):159–168CrossRef
33.
de França Neto AH, Rogatto S, Do Amorim MM et al (2010) Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol 26(10):708–711PubMedCrossRef
34.
Freeman R, Pollack R, Rosenbloom E (2010) Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 3:1–24
35.
Gerli S, Papaleo E, Ferrari A, Di Renzo GC (2007) Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 11:347–354PubMed
36.
Ghaziuddin M (1988) Polycystic ovary disease, manic-depressive illness and mental retardation. J Intellect Disabil Res 33(4):335–338CrossRef
37.
Ghosh S, Kabir SN, Pakrashi A, et al (1993) Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res Pediatr 39(1–2):61–66
38.
González A, Sáez ME, Aragón MJ et al (2006) Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome. Hum Reprod 21(4):943–951PubMedCrossRef
39.
Goodarzi MO (2007) The Polycystic ovary syndrome: current concepts on pathogenesis and clinical care. B chapter Endocr Updates 27:29–42CrossRef
40.
Grigoriadis S, Seeman MV (2002) The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatr 47:437–442
41.
Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5(5):539–551PubMedCrossRef
42.
Hanzu FA, Radian S, Attaoua R et al (2010) Association of insulin receptor genetic variants with polycystic ovary syndrome in a population of women from Central Europe. Fertil Steril 94(6):2389–2392
43.
Hendrick V, Altshuler LL, Burt VK (1996) Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 4(4):200–2007PubMedCrossRef
44.
Herken H, Erdal M, Aydin N et al (2009) The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 28(10):515–519PubMedCrossRef
45.
Hirschhorn JN, Lohmueller KB, Kirk Byrne E et al (2002) A comprehensive review of genetic association studies. Genet Med 4(2):45–61PubMedCrossRef
46.
Hoff AL, Kremen WS, Wieneke MH et al (2001) Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 158:1134–1139PubMedCrossRef
47.
Hoffer A (2001) Thyroid and Schizophrenia. J Orthomol Med 16(4):205–212
48.
Huang MC, Lu ML, Tsai CJ et al (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120(4):274–280PubMedCrossRef
49.
Indhavivadhana S, Wongwananuruk T, Rattanachaiyanont M et al (2010) Prevalence of metabolic syndrome in reproductive-aged polycystic ovary syndrome Thai women. J Med Assoc Thail 93(6):653–660
50.
Janssen OE, Mehlmauer N, Hahn S et al (2004) High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 150(3):363–369PubMedCrossRef
51.
Johnstone EC, Owens DG, Crow TJ et al (1986) Hypothyroidism as a correlate of lateral ventricular enlargement in manic-depressive and neurotic illness. British J Psychiatry 148:317–321CrossRef
52.
Joffe H, Cohen LS, Suppesb T et al (2006) Longitudinal follow-up of reproductive and metabolic features of Valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 60(12):1378–1381PubMedCrossRef
53.
Joffe H, Hall JE, Cohen LS et al (2003) A putative relationship between Valproic Acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 11(2):99–108PubMedCrossRef
54.
Joffe H, Hayes FJ (2008) Menstrual cycle dysfunction associated with neurological and psychiatric disorders. Their treatment in adolescents. Ann N Y Acad Sci 1135:219–229 (Issue The Menstrual Cycle and Adolescents)PubMedCrossRef
55.
Kelly DL, Conley RR (2005) Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 66(1):80–84PubMedCrossRef
56.
Ko YH, Joe SH, Cho W et al (2006) Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53(4):169–175PubMedCrossRef
57.
Kopala LC, Lewine R, Good KP et al (1997) Clinical features of schizophrenia in a woman with hyperandrogenism. J Psychiatry Neurosci 22(1):56–60PubMed
58.
Koponen HJ, Hakko HH, Saari KM et al (2010) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J biol Psychiatry 11(2Pt2):262–267PubMedCrossRef
59.
Kulkarni J (2009) Oestrogen–a new treatment approach for schizophrenia? Med J Aust 190(4 Suppl):S37–38PubMed
60.
Kulkarni J (2010) Special issues in managing long-term mental illness in women. Int Rev Psychiatry 22(2):183–190PubMedCrossRef
61.
Kulkarni J, Riedel A, de Castella AR et al (2010) Estrogen—a potential treatment for schizophrenia. Schizophr Res 48(1):137–144CrossRef
62.
Strauss LegroRS, III JF (2001) Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78(3):569–576
63.
Lindley SE, Schröder CM, O`Hara R.(2008) Insulin resistance syndrome and neuropsychiatric disease Informa pp. 49-53
64.
Mackin P, Ruttledge S. Physical comorbidity in bipolar disorder. Med Psychiatr Ser 2007/35; pp 391-394
65.
Mantel N (1963) Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58(303):690–691
66.
Martinos A, Rinieris P, Souvatzoglou A et al (1986) Effects of six weeks’ neuroleptic treatment on the pituitary-thyroid axis in schizophrenic patients. Biol Psychiatry 16:2–3
67.
Matsunaga H, Sarai M (1993) Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Psychiatry Clin Neurosci 47(4):825–842CrossRef
68.
Nestler JE, Jakubowicz DJ (1997) Lean women with PCOS respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 82(12):4075–4079PubMedCrossRef
69.
Normand ST, Jou KH (2002) Sample size considerations in observational health care quality studies. Stat Med 21:331–345PubMedCrossRef
70.
Oud MJ, Meyboom-de Jong B (2009) Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 9(10):32CrossRef
71.
Padmavati R (2010) Metabolic syndrome in mental disorders. Indian J Med Res 131:11–13PubMed
72.
Pantasri T, Vutyavanich T, Sreshthaputra O et al (2010) Metabolic syndrome and insulin resistance in Thai women with polycystic ovary syndrome. J Med Assoc Thail 93(4):406–412
73.
Pethö B, Karczag I, Czeizel A (1982) Familially accumulated schizophrenia (folie à cinq) in association with Stein–Leventhal syndrome. Psychiatria Clinica (Basel) 15(4):206–211
74.
Pethö B, Karczag I, Czeizel E (1981) Stein-Leventhal syndrome associated with cumulative familial schizophrenia (folie à cinq). Orv Hetil 122(48):2965–2966PubMed
75.
Philibert RA, Sandhu HK, Hutton AM et al (2001) Population-based association analyses of the HOPA 12bp polymorphism for schizophrenia and hypothyroidism. Am J Med Genet Part B Neuropsychiatr Genet 105(1):130–134CrossRef
76.
Prentice R (1976) Use of the logistic model in retrospective studies. Biometrics 32(3):599–606PubMedCrossRef
77.
Rao ML, Kölsch H (2003) Effects of estrogen on brain development and neuroprotection–implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28(Suppl 2):83–96PubMedCrossRef
78.
Rasgon NL.(2001) Investigating polycystic ovary syndrome in women with bipolar disorder. Psychiatr Times 18(5)
79.
de Resende LO, dos Reis RM, Ferriani RA et al (2010) Concentration of steroid hormones in the follicular fluid of mature and immature ovarian follicles of patients with polycystic ovary syndrome submitted to in vitro fertilization. Ravista Brasileira de Gynecologia e Obstetr 32(9):447–453CrossRef
80.
Rheingold JC (1939) Autonomic integration in schizophrenia. Autonomic status determined statistically, the thyroid factor, and a possible thyroid-hypothalamus mechanism. Psychosom Med 1:397–413
81.
Riecher-Rössler A.(2005) Estrogens and schizophrenia. Estrogen Effects in Psychiatric Disorders, pp. 31-52
82.
Riecher-Rössler A, Häfner H, Stumbaum M et al (1994) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20(1):203–214PubMed
83.
Roepke S, Ziegenhorn A, Kronsbein J et al (2010) Incidence of polycystic ovaries and androgen serum levels in women with borderline personality disorder. J Psychiatr Res 44(13):847–852PubMedCrossRef
84.
Ryan WG, Roddam RF, Grizzle WE (1994) Thyroid function screening in newly admitted psychiatric inpatients. Ann Clin Psychiatry 6(1):7–12PubMedCrossRef
85.
Sandhu HK, Sarkar M, Turner BM et al (2003) Polymorphism analysis of HOPA: a candidate gene for schizophrenia. Am J Med Genet 123B(1):33–38PubMedCrossRef
86.
Seeman MV, Lang M (1990) The role of estrogens in schizophrenia gender differences. Schizophr Bull 16(2):185–194PubMed
87.
Shikaeva FV, Efimenko NF (1994) Hormonal-mediator interrelationships in polycystic ovary syndrome. Problemi Endocrinologii 40(4):33–35
88.
Simson GM, Cranswick EH, Blair ChB (1963) Thyroid indeces in chronic schizophrenia. Nerv Ment Dis 137(6):582–590CrossRef
89.
Smirnova LK, Zorenko TI ((1993)) Thyroid functional activity in schizophrenic patients with aggressive sexual behavior. Zhurnal Nevrologi I Psikhiatrii Imeni S. S. Korsakova 93(4):68–70
90.
Sonino N, Peruzzi P (2009) A psychoneuroendocrinology service. Psychother Psychosom 78(6):346–351PubMedCrossRef
91.
Sridhar GR, Nagamani G (1993) Hypothyroidism presenting with polycystic ovary syndrome. J Assoc Physicians-India 41(2):88–90PubMed
92.
Steiner J, Walter M, Guest P et al (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15(1):3–4PubMedCrossRef
93.
Sundararaman PG, Shweta, Sridhar GR (2008) Psychosocial aspects of women with polycystic ovary syndrome from South India. J Assoc Physicians India 56: 945–948
94.
Sutton AJ, Abrams KR, Lambert PC, et al. Meta-analysis in practice: a critical review of available software. Biostatistics; In: Meta-Analysis in Medicine and Health Policy, 2000. New York, Marcel Dekker
95.
Takeuchi T, Tsutsumi O, Taketani Y (2008) Abnormal response of insulin to glucose loading and assessment of insulin resistance in non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol 24(7):385–391PubMedCrossRef
96.
Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8(1):41PubMedCrossRef
97.
Verma SK, Subramaniam M, Liew A, Poon LY (2009) Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 70(7):997–1000PubMedCrossRef
98.
Vicennati V, Gambineri A, Calzoni F et al (1998) Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47(8):988–992PubMedCrossRef
99.
Vuguin PM (2010) Interventional studies for polycystic ovarian syndrome in children and adolescents. Pediatr Health 4(1):59–73CrossRef
100.
Wagner KD, Kowatch RA.(2001) Child and adolescent bipolar disorder: focus on differential diagnosis and management. A Monograph of Continuing Medical Education Credit, IL
101.
Weber NS, Cowan DN, Millikan AM, Niebuhr DW (2009) Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv 60(8):1059–1067PubMedCrossRef
102.
West GR (1986) A stochastic analysis of an input-output model. Econometrica 54(2):363–374CrossRef
103.
Wheeler CJ, Keye WR, Peterson CM. (2010) Polycystic ovary syndrome. Reproductive Endocrinology and Infertility, Part 2, pp 147-182
104.
Wilk AI, Jensen NM, Havighurst TC (1997) Meta-analysis of randomized control trials addressing brief interventions. J Gen Intern Med 12(5):274–283PubMedCrossRef
105.
Yamashita Y, Kawamura T, Rumi Fujikawa R et al (2006) Regression of both pituitary and ovarian cysts after administration of Thyroid hormone in a case of primary hypothyroidism. Intern Med 40(8):751–755CrossRef
Metadaten
Titel
Schizophrenia and Stein–Leventhal syndrome: comorbidity features
verfasst von
Naira R. Matevosyan
Publikationsdatum
01.10.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-011-1963-1

Weitere Artikel der Ausgabe 4/2011

Archives of Gynecology and Obstetrics 4/2011 Zur Ausgabe

General Gynecology

Anatomical study of position of the TVT-O to the obturator nerve influenced by the position of the legs during the procedure: based upon findings at formalin-embalmed and fresh-frozen bodies

Gynecologic Oncology

Multiple myeloma and pregnancy: a case report and literature review

General Gynecology

A prospective randomised study of total laparoscopic hysterectomy, laparoscopically assisted vaginal hysterectomy and non-descent vaginal hysterectomy for the treatment of benign diseases of the uterus

Materno-fetal Medicine

Transvaginal ultrasound of cervical length and its correlation to digital cervical examination, time to spontaneous labor and mode of delivery

Materno-fetal Medicine

Fetal loss associated with second trimester amniocentesis

Materno-fetal Medicine

Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise